Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis

Peter H Gilligan, Damian G Downey, J Stuart Elborn, Patrick A Flume, Sebastian Funk, Deirdre Gilpin, Timothy J Kidd, John McCaughan, B Cherie Millar, Philip G Murphy, Jacqueline C Rendall, Michael M Tunney, John E Moore

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
62 Downloads (Pure)


Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.

Original languageEnglish
Pages (from-to)1-23
JournalJournal of Clinical Microbiology
Early online date06 Jun 2018
Publication statusEarly online date - 06 Jun 2018
Externally publishedYes


Dive into the research topics of 'Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis'. Together they form a unique fingerprint.

Cite this